Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
暂无分享,去创建一个
J Hermans | A. Gratwohl | D. Niederwieser | J. Hermans | J. Goldman | H. Prentice | F. Frassoni | A. Bacigalupo | T. D. de Witte | W. Arcese | J. Apperley | H G Prentice | D. Bunjes | A Gratwohl | H J Kolb | H. Kolb | G. Bandini | A. Devergie | D Bunjes | A P Iori | W Arcese | F Frassoni | A Bacigalupo | D Niederwieser | C Guglielmi | G Bandini | E Carreras | A Devergie | J Goldman | T de Witte | J Apperley | C. Guglielmi | E. Carreras | A. Iori
[1] J. Radich,et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. , 1995, Blood.
[2] David E. Matthews,et al. Using and Understanding Medical Statistics , 1984 .
[3] A. Rimm,et al. ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA , 1984, The Lancet.
[4] R. Collins,et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. , 1992, Bone marrow transplantation.
[5] R. Storb,et al. Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. , 1988, Bone marrow transplantation.
[6] H. Deeg,et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. , 1986, Annals of internal medicine.
[7] F. Frassoni,et al. Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia , 1988, British journal of haematology.
[8] G. Gahrton,et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation , 1997, Bone Marrow Transplantation.
[9] J. Goldman,et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. , 1994, Blood.
[10] W. Gregory,et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect , 1988, British journal of haematology.
[11] B. Chapuis,et al. Adoptive immunotherapy for recurrent CML after BMT. , 1993, Bone marrow transplantation.
[12] W. Wilmanns,et al. Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .
[13] S. Thibodeau,et al. Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1992, Bone marrow transplantation.
[14] A. Barrett,et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation [letter] , 1992 .
[15] J. Reiffers,et al. Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. , 1990, Bone marrow transplantation.
[16] F. Aversa,et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. , 1993, Blood.
[17] M. Horowitz,et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose , 1993 .
[18] J. Goldman,et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors , 1998, Bone Marrow Transplantation.
[19] D. Porter,et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. , 1994, The New England journal of medicine.
[20] C. Higano,et al. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. , 1992, Blood.
[21] F. Mandelli,et al. Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation. , 1990, Bone marrow transplantation.
[22] K. Sullivan,et al. HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. , 1988, Blood.
[23] A. Gratwohl,et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A REPORT BY THE EBMT LEUKAEMIA WORKING PARTY , 1991, British journal of haematology.
[24] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.
[25] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[26] H. Kantarjian,et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1995, Blood.
[27] F. Aversa,et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group , 1993 .
[28] S. Knuutila,et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: a metaphase‐FISH study , 1996, British journal of haematology.
[29] J. Ritz,et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Mackinnon,et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.
[31] G. Morgan,et al. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. , 1991, Blood.
[32] J. Goldman,et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. , 1993 .
[33] R. Champlin. T-cell depletion for allogeneic bone marrow transplantation: impact on graft-versus-host disease, engraftment, and graft-versus-leukemia. , 1993, Journal of hematotherapy.
[34] M. Horowitz,et al. Second HLA-identical sibling transplants for leukemia recurrence. , 1992, Bone marrow transplantation.
[36] H. Heimpel,et al. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. , 1993, Transplantation.
[37] R. Hoffmann,et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .